PMID- 35378925
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20220406
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 16
DP  - 2022
TI  - Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced 
      Cervical Carcinoma: A Retrospective Study.
PG  - 887-897
LID - 10.2147/DDDT.S358302 [doi]
AB  - PURPOSE: Programmed cell death protein 1 (PD-1) inhibitors have shown a 
      therapeutic effect in the treatment of advanced cervical cancer in clinical 
      trials. However, the clinical characteristics associated with response remain 
      undetermined. This study aimed to evaluate the efficacy and prognostic factors of 
      PD-1 inhibitors in patients with advanced cervical cancer in clinical practice. 
      PATIENTS AND METHODS: The study enrolled patients with recurrent or metastatic 
      cervical cancer treated with PD-1 inhibitors at our center between March 2018 and 
      November 2020. The primary outcomes were the objective response rate (ORR) and 
      progression-free survival (PFS). Secondary endpoints were overall survival (OS) 
      and safety. In addition, independent prognostic factors were identified by 
      multivariate regression analysis. RESULTS: A total of 102 patients were included, 
      and the ORR and disease control rate (DCR) were 51.0% and 66.7%, respectively. 
      Median PFS was 11.0 months (95% CI, 1.7-20.4), while median OS was not achieved. 
      Multivariate analysis indicated that factors associated with a better prognosis 
      (ORR and PFS) included squamous cell carcinoma, a time to recurrence >6 months, 
      and PD-1 plus chemotherapy and anti-angiogenic drugs (p < 0.05). Lines of therapy 
      were independent factors for ORR but not for PFS. We also observed a tendency for 
      longer PFS in patients with lung metastases and lymph node metastases only. 
      Treatment-related adverse events (AEs) were well tolerated and primarily included 
      thrombocytopenia, hepatic dysfunction, anemia, and leukopenia. CONCLUSION: PD-1 
      inhibitors demonstrated beneficial efficacy and safety in advanced cervical 
      cancer, particularly for patients with squamous cell carcinoma, a time to 
      recurrence >6 months, or PD-1 plus chemotherapy and anti-angiogenic drugs. 
      Further studies are needed to confirm the long-term outcomes.
CI  - (c) 2022 Cheng et al.
FAU - Cheng, Mingxia
AU  - Cheng M
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, People's Republic of China.
FAU - Wang, Haihong
AU  - Wang H
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, People's Republic of China.
FAU - Zhao, Yingchao
AU  - Zhao Y
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, People's Republic of China.
FAU - Li, Guiling
AU  - Li G
AUID- ORCID: 0000-0003-0149-499X
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, 430022, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220329
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Lung Neoplasms/drug therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Uterine Cervical Neoplasms/drug therapy
PMC - PMC8976502
OTO - NOTNLM
OT  - PD-1
OT  - anti-angiogenic therapy
OT  - cervical cancer
OT  - chemotherapy
OT  - immune checkpoint inhibitors
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/04/06 06:00
MHDA- 2022/04/07 06:00
PMCR- 2022/03/29
CRDT- 2022/04/05 05:14
PHST- 2022/01/13 00:00 [received]
PHST- 2022/03/19 00:00 [accepted]
PHST- 2022/04/05 05:14 [entrez]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2022/03/29 00:00 [pmc-release]
AID - 358302 [pii]
AID - 10.2147/DDDT.S358302 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2022 Mar 29;16:887-897. doi: 10.2147/DDDT.S358302. 
      eCollection 2022.